Patent FR2350849A1 successfully refreshed from Google Patents.
Patent EP0526756A1 successfully refreshed from Google Patents.
EP0526756A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Composition for revitalizing scar tissue
Assignee: CR Bard Inc
•
Filing: 1992-07-09
•
Granted: —
•
Expires: 2012-07-09
Abstract
Abstract A composition is provided that is effective in revitalizing scar tissue by introducing a bioactive substance having angiogenic activity into the scar tissue. The bioactive substance can be introduced by itself, or it can be introduced into the scar tissue in a timed release form. The present invention is effective in treating stress urinary incontinence or localized muscular dysfunction.
Inventors
- 👤 Clarence C. Lee
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 12:34
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1658; A61K31/00; A61K31/557; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K38/1858; A61K38/22; A61K38/27; A61K38/30; A61K38/39; A61K9/1611; A61K9/1652; A61P; A61P13/00; A61P13/02; A61P15/00; A61P3/00; A61P43/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
35 words
A pharmaceutical composition for revitalizing scar tissue in a human or animal comprising a bioactive material selected from naturally occurring growth factors, active peptide segments of various growth factors, synthetic growth factors and admixtures thereof.
Claim 2
Dependent Claim
35 words
A pharmaceutical composition for revitalizing scar tissue in a human or animal comprising a bioactive material selected from naturally occurring growth factors, active peptide segments of various growth factors, synthetic growth factors and admixtures thereof.
Claim 3
Dependent Claim
66 words
The composition of claim 1, characterized in that the composition additionally comprises a pharmaceutically acceptable controlled release matrix selected from collagen, gelatin, albumin, chondroitin sulfate, hyaluronic acid, heparin, oxidized cellulose, dextran, polyglycolic acid, polylactic acid and polyanhydride, whereby the bioactive material is immobilized in the matrix and is present in an amount of 0.01-35% by weight based on the total weight of bioactive material and matrix.
Claim 4
Dependent Claim
40 words
The composition of any of claims 1 and 2, characterized in that the composition is mixed with a liquid carrier, whereby the composition is present in an amount of 0.001-23% by weight based on the total weight of the mixture.
Claim 5
Dependent Claim
18 words
The composition of any of claims 1-3, characterized in that the naturally occurring growth factor is growth hormone.
Claim 6
Dependent Claim
19 words
The composition of any of claims 1-3, characterized in that the naturally occurring growth factor is insulin-like growth factor.
Claim 7
Dependent Claim
19 words
The composition of any of claims 1-3, characterized in that the naturally occurring growth factor is platelet-derived growth factor.
Claim 8
Dependent Claim
19 words
The composition of any of claims 1-3, characterized in that the naturally occurring growth factor is transforming growth factor.
Claim 9
Dependent Claim
15 words
The composition of any of claims 1-3, characterized in that the bioactive material is fibronectin.
Claim 10
Dependent Claim
16 words
The composition of any of claims 1-3, characterized in that the bioactive material is prostaglandin E.
Claim 11
Dependent Claim
16 words
The composition of claim 7, characterized in that the bioactive material is transforming growth factor beta.
Claim 12
Dependent Claim
16 words
The composition of claim 7, characterized in that the bioactive material is transforming growth factor alpha.
Claim 13
Dependent Claim
29 words
The composition of any of claims 1-10, characterized in that the carrier is selected from aqueous solutions, glycols, nonionic dispersing agents, natural or synthetic oils, alcohols and their combinations.
Claim 14
Dependent Claim
20 words
Use of a composition according to any of claims 1-12 for the manufacture of a drug for revitalizing scar tissue.
References Cited (Backward Citations)
US4774091A
Cited
US4952403A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.